Story detail
Read the key details here, then continue on the original publisher.
Job lock, surging prescription drug costs, No Surprises Act update, and more from STAT's Health Care Inc.
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
The agency is considering whether compounding pharmacies should be allowed to produce BPC-157, TB-500 and other previously banned peptides.
More light at the day’s end comes at a price: much later winter sunrises across much of the U.S. Scientists have documented consequences for public health and the economy.
The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.
The beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.
An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!